Warning letter
Harbin Jixianglong Biotech Co., Ltd.: warning letter of May 1, 2026
FDA warning letter 723330 · Center for Drug Evaluation and Research (CDER)
Key facts
| Reference number | 723330 |
|---|---|
| Company | Harbin Jixianglong Biotech Co., Ltd. |
| Subject | CGMP/API/Adulterated and Misbranded Drugs |
| Issue date | May 1, 2026 |
| Posted date | May 19, 2026 |
| Issuing office | Center for Drug Evaluation and Research (CDER) |
| Product type | Drugs |
| CFR sections cited | 207.49(a)(12), 207, 207.29, 207.41(a) |
| Inspection city | Haerbin |
| Inspection start date | Nov 3, 2025 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: